(P 75) CD248 AS A PROGNOSTIC MARKER IN OSTEOSARCOMA

Objective: Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. However, patient prognosis still relies on the Enneking staging system and necrosis rate, with a lack of effective biomarkers. CD248 is primarily expressed in the stroma, particularly in tumor-associated fibroblasts and pericytes, and is also expressed in tumor cells of most sarcomas. The aim of this study was to evaluate the expression level of CD248 in osteosarcoma and its impact on patient prognosis.

Methods: Immunohistochemical analysis was performed on osteosarcoma tissue microarrays to detect CD248 expression in tumor tissues. Follow-up data were used to investigate the relationship between CD248 protein expression and osteosarcoma patients, with clinical data serving as evidence to confirm the significant role of CD248 in the progression of osteosarcoma. Survival analysis was conducted using Kaplan-Meier curves, with a p-value < 0.05 considered statistically significant.

Results: The study included 99 osteosarcoma patients, of whom 56 were CD248-positive and 43 were CD248-negative. The median follow-up time was 41 months (range: 0.5–118.4 months). A statistically significant difference in survival was observed between CD248-positive and CD248-negative groups. The CD248-positive group (median survival: 48.2 months) had significantly worse survival than the CD248-negative group (median survival: 79.5 months).

Conclusion: CD248 expression has prognostic significance in osteosarcoma, with CD248-positive patients exhibiting poorer outcomes.